Discover

Back to filter

Related topics

Intoducing cellenONE: The revolutionary Single Cell isolator

Cellenion

May 25, 2022

A revolutionary platform based on sciDROP PICO precision dispensing technology and coupled with advanced image...

Advances in Leukemia research using shear flow and Bioflux system

Fluxion Biosciences

May 24, 2022

Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...

Why use Cytek Aurora?

Cytek Biosciences

May 4, 2022

A prodigy incorporating a unique combination of patent-pending innovative technologies that takes flow cytometry to the...

Introducing Celloger Mini Plus: Automated and compact Live cell imaging inside your incubator

Curiosis

Apr 11, 2022

We are happy to introduce new Celloger Mini Plus, automated live cell imaging system! Click the video below to find out...

CQ1 live-cell confocal system: revealing the pathophysiology of COVID-19 infection

Yokogawa

Mar 21, 2022

Yokogawa decided to support the world’s fight against COVID-19, scientifically cooperating with research facilities...

In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers

MOLECUBES

Mar 9, 2022

Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...

Introducing IsoPlexis Single-Cell Natural Killer Panel

IsoPlexis

Mar 4, 2022

Because of their ability to kill tumour cells, NK cells are an attractive target in cancer immunotherapy, therapeutic...

Enhanced small particle detection on CytekAurora and Northern Lights

Cytek Biosciences

Mar 2, 2022

Aurora system with ESP option, can  fully resolve particles around 70nm and from the 80nm PS bead. The new violet laser...

Quantitative 3D Optical Imaging for Lago

Spectral Instruments Imaging

Feb 21, 2022

Spectral Instrument Imaging just announced a new, strategic partnership with InVivo Analytics, which enables...

Molecular imaging study design basics

Spectral Instruments Imaging

Jan 31, 2022

By combining study design, study management, and image analytics in all major imaging modalities, BioLaurus has...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey